Biomics Biopharma (ASX:BBM) Days Payable: 0.00 (As of . 20)


What is Biomics Biopharma Days Payable?

Biomics Biopharma ASX:BBM Days Payable is 0.00 as of . 20.

Biomics Biopharma's average Accounts Payable for the six months ended in . 20 was A$0.00 Mil. Biomics Biopharma's Cost of Goods Sold for the six months ended in . 20 was A$0.00 Mil.

The historical rank and industry rank for Biomics Biopharma's Days Payable or its related term are showing as below:

ASX:BBM's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.56
* Ranked among companies with meaningful Days Payable only.

Biomics Biopharma's Days Payable stayed the same from . 20 (0.00) to . 20 (0.00).

Biomics Biopharma Days Payable Historical Data

* Premium members only.

The historical data trend for Biomics Biopharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomics Biopharma Days Payable Chart

Biomics Biopharma Annual Data
Trend
Days Payable

Biomics Biopharma Semi-Annual Data
Days Payable

Biomics Biopharma Days Payable Competitor Comparison

For the Biotechnology subindustry, Biomics Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomics Biopharma Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomics Biopharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Biomics Biopharma's Days Payable falls into.


Biomics Biopharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Biomics Biopharma's Days Payable for the fiscal year that ended in . 20 is calculated as

Days Payable (A: . 20 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: . 20 ) + Accounts Payable (A: . 20 )) / count ) / Cost of Goods Sold (A: . 20 )*Days in Period
=( ( + ) / 1 ) / *365
=0 / *365
=N/A

Biomics Biopharma's Days Payable for the quarter that ended in . 20 is calculated as:

Days Payable (Q: . 20 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: . 20 ) + Accounts Payable (Q: . 20 )) / count ) / Cost of Goods Sold (Q: . 20 )*Days in Period
=( ( + ) / 1 ) / *365 / 2
=0 / *365 / 2
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Biomics Biopharma (ASX:BBM) has a Days Payable of 0.00 as of . 20. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biomics Biopharma and its competitors.
Is Biomics Biopharma's Days Payable too high?
Biomics Biopharma's current Days Payable is 0.00.
How does Biomics Biopharma's Days Payable compare to competitors?
Biomics Biopharma's Days Payable of 0.00 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 113.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biomics Biopharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomics Biopharma's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomics Biopharma stock overvalued right now?
Biomics Biopharma (ASX:BBM) has a current Days Payable of 0.00. The current Days Payable is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Biomics Biopharma (ASX:BBM), the current Days Payable is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomics Biopharma Business Description

Address 1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000
Biomics Biopharma Ltd is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.